Conclusion
The findings of the present study demonstrate that ambroxol hydrochloride combined with amoxicillin potassium clavulanate combination might be a reliable approach for the treatment of bronchopneumonia in children. It can synergistically relieve inflammation with high safety profiles.
Methods
From January 2018 to June 2019, 100 children with bronchopneumonia admitted to the Pediatric Department of Nanjing Pukou District Hospital of Traditional Chinese Medicine were enrolled as the study subjects. The children were assigned either to an observation group or a control group in a ratio of 1:1 using the random alphabet method. The observation group was treated with ambroxol hydrochloride plus amoxicillin potassium clavulanate combination, and the control group was treated with amoxicillin potassium clavulanate combination. The therapeutic efficiency and serum white blood cells (WBC), C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α) were compared between the two groups.
Objective
The goal of the present study was to examine the effect of ambroxol hydrochloride combined with amoxicillin potassium clavulanate combination on children with bronchopneumonia and its influence on the level of inflammatory factors.
Results
Regarding the effective rate of treatment, the observation group (94%) was observed to be notably higher as compared to the control group (84%). The levels of WBC, CRP, IL-6, and TNF-α were reported to be significantly lower in the two groups after treatment. The WBC, CRP, IL-6, and TNF-α after treatment in the observation group were lower than those in the control group. The time for clinical symptoms to disappear of fever, cough, asthma, and pulmonary rales was all shorter in the observation group.